ArticleCureus2025
Enhancing Endoscopic Dacryocystorhinostomy: A Novel Transethmoidal Approach to the Lacrimal Fossa.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopic dacryocystorhinostomy (EE-DCR) has been established as an effective strategy for managing lower nasolacrimal duct obstructions (L-NLDOs). Although several techniques have been proposed, none have demonstrated superior outcomes. We developed a novel transethmoidal approach to the lacrimal fossa, which embodies the fundamental principles of endoscopic sinus surgery. Images and video are presented to describe the procedure and for educational purposes. Patients with unilateral L-NLDO were evaluated preoperatively (T0), at 6 months (T1), and 12 months (T2) postoperatively. Surgical success was defined as complete (patency on irrigation with symptom resolution) or anatomical (patency with persistent epiphora). Overall, surgical success was achieved in 308/365 (84.4%) patients at T1 and in 317/365 (86.9%) patients at 12 T2. At T1, 155/365 (42.47%) patients achieved complete success, and 153/365 (41.49%) anatomical success. At T2, 215/365 (58.90%) had complete success, and 102/365 (27.94%) had anatomical success. Minor complications (n = 13/365, 5.56%) were managed intraoperatively. The mean procedure duration was 37.40 ± 12.12 minutes. In our experience, this approach guaranteed favorable results and low complication rates, with reasonably short procedural times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.